BJH - volume 7, issue Abstract Book BHS, january 2016
S. Faict , A. De Becker MD, K. Fostier MD, F. Trullemans , R. Schots MD, PhD
BJH - volume 7, issue Abstract Book BHS, january 2016
B. Heyrman MD, A. De Becker MD, R. Schots MD, PhD
BJH - volume 6, issue Abstract Book BHS, january 2015
B. Heyrman MD, A. De Becker MD, K. Fostier MD, F. Trullemans , R. Schots MD, PhD
BJH - volume 5, issue Abstract Book BHS, january 2014
X. Galloo , C. Caron , L. Pipeleers , K. Wissing , K. Fostier MD, F. Trullemans , C. Tielemans , R. Schots MD, PhD, A. De Becker MD
BJH - volume 4, issue 1, march 2013
K. Fostier MD, A. De Becker MD, R. Schots MD, PhD
The immunomodulatory drugs (IMiDs) are a class of orally available compounds which are licensed for the treatment of multiple myeloma (thalidomide, lenalidomide) and transfusion-dependent low- and intermediate-risk myelodysplasia (MDS) with deletion of long arm of chromosome 5 (lenalidomide). Pomalidomide, a novel second generation IMiD, is entering clinical trials and seems to further broaden the therapeutic spectrum of these already pleiotropic drugs. Here we summarise new insights into the mechanism of action of IMiDs as well as new developments related to their clinical use, as maintenance therapy in multiple myeloma (MM), in the treatment of myeloproliferative neoplasm- associated myelofibrosis, other types of MDS, chronic lymphocytic leukaemia (CLL) and sickle cell disease (SCD).
(BELG J HEMATOL 2013;1:21–28)
Read moreBJH - 2013, issue BHS Abstractbook, january 2013
C. Caron , A. De Becker MD, K. Fostier MD, M. De Waele , H. De Raeve MD, PhD, R. Schots MD, PhD, F. Trullemans
BJH - 2013, issue BHS Abstractbook, january 2013
N. De Beule , K. Fostier MD, A. De Becker MD, C. Caron , F. Trullemans , R. Schots MD, PhD
Top
